WILMINGTON, Del.– AstraZeneca has launched a new direct-to-consumer online platform, AstraZeneca Direct, designed to make it easier for eligible U.S. patients to access their prescribed medications at a transparent cash price with the convenience of home delivery.
The service will begin October 1, 2025, and initially offer AIRSUPRA (albuterol/budesonide) and FARXIGA (dapagliflozin) at up to 70 percent off the list price. Patients will also be able to order FLUMIST (Influenza Vaccine Live, Intranasal) for delivery through the platform.
AstraZeneca said the initiative is intended to support patients living with chronic conditions such as asthma, diabetes, heart failure, and chronic kidney disease, as well as those seeking flu protection.
“We remain deeply committed to improving accessibility, affordability, and driving innovation in healthcare, and we are excited to launch AstraZeneca Direct, which will give patients a transparent cash price with the convenience of home delivery,” said Joris Silon, U.S. Country President, AstraZeneca. “The program complements our existing patient support services and is an important step forward in offering patients the medication they need, when and how they need it.”
The new platform expands on the company’s existing U.S. patient support programs, which will continue unchanged. Those programs help many eligible patients access AstraZeneca medications at no cost or at a reduced cost.
Patients can begin using AstraZeneca Direct at AstraZenecaDirect.com starting Wednesday, October 1, 2025.
